Physician profile
Verlan T Marshall
NPI 1780770180
$1,034.02
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $259 · 2021: $448 · 2022: $107 · 2023: $51.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $51.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $51.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $188.63 | 2020-2021 | |
| Vaporox, INC. | $157.07 | 2020 | |
| Abbott Laboratories | $127.48 | 2021 | |
| Biom'Up France Sas | $100.38 | 2021 | |
| Smith+Nephew, INC. | $72.48 | 2019-2021 | |
| Aap Implants INC | $52.12 | 2021-2022 | |
| Djo, LLC | $37.29 | 2022 | |
| Wright Medical Technology, INC. | $37.09 | 2019 | |
| Tactile Systems Technology INC | $35.58 | 2019 | |
| Abbvie INC. | $31.59 | 2023 | |
| Arteriocyte Medical Systems, INC. | $26.71 | 2022 | |
| Merck Sharp & Dohme LLC | $26.23 | 2019 | |
| Linvatec Corporation | $26.11 | 2019 | |
| Anika Therapeutics, INC. | $21.78 | 2021 | |
| Baudax Bio INC. | $20.54 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $20.17 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Treace Medical Concepts, INC. | $16.51 | 2022 | |
| Alfasigma USA, INC. | $14.32 | 2021 | |
| Orthofix Medical, INC. | $14.04 | 2019 | |
| In2bones USA, LLC | $7.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Verlan Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.